Gefitinib affects functions of platelets and blood vessels via changes in prostanoids balance.

摘要: Prostaglandins (PGs) and thromboxane (TX) produced by cyclooxygenase (COX) have a great influence on vascular systems platelet functions. The serum levels of epidermal growth factor (EGF) PGs were measured in patients with lung cancer treated gefitinib, the EGF aggregation was investigated. Twenty level TXB(2) increased significantly all who received gefitinib for 2 weeks (before vs. after = 94.1 +/- 47.3 190.9 54.3, p<0.01). also responders without concurrent chemotherapy 79.3 35.5 194.5 58.1, p<0.05), but not non-responders 106. 5 65.8 162.2 52.8, N.S.). PG 6-keto F1alpha PGE(2) did exhibit significant changes. Furthermore, showed no change (after before 234 35 276 72, Although there correlation between (N.S.), F2alpha/TXB(2) ratio decreased 0.054 0.018 vs 0.033 0.015, p<0.05). secondary observed high-dose adenosine diphosphate stimulation inhibited 1-minute preincubation EGF. Platelet administration tended to accelerate low-dose stimulation. We conclude that careful observation is needed chronic obstructive pulmonary disease, fibrosis, thromboembolic diseases receiving gefitinib. measurement prostanoids may be good predictor beneficial adverse effects. Moreover, combination COX inhibitor regulates TXA(2)/PGI(2) balance should evaluated.